• TMRE Mitochondrial Membrane Potential Assay Kit: Applied Wor

  2026-05-06

  The TMRE mitochondrial membrane potential assay kit enables high-sensitivity, quantitative detection of mitochondrial health across diverse sample types. Integrated controls and robust protocols empower researchers to dissect energy metabolism, apoptosis, and bioenergetic disruption with reproducibility and confidence.

• Unlocking CRISPR Precision: The Role of Cap1 Cas9 mRNA in Tr

  2026-05-05

  Explore how rational engineering of mRNA with Cap1 structure, as exemplified by EZ Cap™ Cas9 mRNA (m1Ψ), enables next-level CRISPR-Cas9 genome editing. This article integrates mechanistic insights, recent advances in mRNA nuclear export modulation, and practical guidance for translational researchers, bridging product innovation with evolving best practices.

• TRIM21-ERK1/2 Axis Drives Proliferation and Resistance in Pi

  2026-05-05

  This study uncovers a mechanistic role for TRIM21 in promoting cell proliferation and drug resistance in pituitary adenomas by modulating ERK1/2 ubiquitination and phosphorylation. By identifying Quisinostat as an agent that downregulates TRIM21 and restores drug sensitivity, the research offers a rationale for targeting this pathway in resistant tumor models.

• Nintedanib (BIBF 1120): Enhancing Antiangiogenic Cancer Rese

  2026-05-04

  Nintedanib (BIBF 1120) delivers precise, multi-pathway angiokinase inhibition, transforming experimental workflows in cancer and fibrosis models. This guide translates cutting-edge findings into actionable protocols, troubleshooting, and advanced applications—empowering researchers to accelerate discoveries using APExBIO's trusted product.

• Chronic ONX-0914 Modulates Hippocampal LTP and Gene Expressi

  2026-05-04

  Maltsev et al. investigated the effects of chronic ONX-0914 administration on synaptic plasticity and gene expression in the mouse hippocampus, revealing that non-constitutive proteasome inhibition selectively impairs tetanus-evoked long-term potentiation (LTP) without affecting theta-burst-induced LTP. These findings clarify the distinct roles of immunoproteasome activity in neuronal signaling and memory formation, with implications for targeted CNS research.

• Nintedanib (BIBF 1120): Mechanistic Insights to Translationa

  2026-05-03

  Explore how Nintedanib (BIBF 1120), a triple angiokinase inhibitor, is redefining translational research paradigms in oncology and fibrosis. This thought-leadership article synthesizes emerging mechanistic evidence, strategic workflow guidance, and actionable protocol parameters—illuminating opportunities for researchers to accelerate discovery in ATRX-deficient cancer models and beyond.

• Azithromycin and Roxithromycin as Novel Senolytics in Fibrob

  2026-05-02

  Ozsvari et al. (2018) identified azithromycin and roxithromycin, two clinically approved macrolide antibiotics, as selective senolytic agents capable of efficiently eliminating senescent human fibroblasts. Their study provides mechanistic insights and introduces a streamlined drug screening strategy, supporting further translational research in cellular aging and senescence-targeted therapeutics.

• Coronavirus Macrodomains Counteract PARP-Mediated Antiviral

  2026-05-02

  Grunewald et al. (2019) reveal that the coronavirus macrodomain is essential for evading PARP-mediated inhibition of viral replication and for limiting host interferon responses. This study clarifies the interplay between viral macrodomains and host poly (ADP-ribose) polymerases, identifying PARP12 and PARP14 as critical factors in innate immunity and suggesting new avenues for antiviral research.

• RG108: Redefining Epigenetic Precision in Cancer Research

  2026-05-01

  Discover how RG108, a potent DNA methyltransferase inhibitor, unlocks new strategies for precise epigenetic gene regulation in cancer research. This in-depth analysis uniquely explores RG108’s selective demethylation and practical assay protocols, bridging molecular innovation with experimental application.

• circ0043898 and KRAS Modulate Esophageal Cancer Stemness

  2026-04-30

  Wang et al. (2025) demonstrate that overexpression of circ0043898 suppresses cancer stem cell properties in esophageal cancer cells, while KRAS overexpression counteracts this effect. These findings provide mechanistic insight into circRNA-mediated regulation of tumor stemness, highlighting new avenues for therapeutic targeting and biomarker development in esophageal cancer.

• Nadolol (SQ-11725): Protocols and Troubleshooting in Cardiov

  2026-04-30

  Nadolol (SQ-11725) stands out as a robust, non-selective beta-adrenergic receptor blocker for preclinical hypertension and angina pectoris studies. This article details stepwise protocols, workflow enhancements, and practical troubleshooting tips—empowering researchers to harness APExBIO’s trusted formulation for reliable, reproducible results.

• PD0325901 (SKU A3013): Reliable MEK Inhibition for Oncology

  2026-04-29

  This article provides a scenario-driven, evidence-based guide for biomedical researchers seeking reproducible MEK pathway inhibition using PD0325901 (SKU A3013). Drawing from recent literature and validated experimental protocols, it demonstrates how PD0325901 addresses workflow challenges in cell viability, proliferation, and apoptosis assays. APExBIO’s SKU A3013 is highlighted for its data-backed reliability and usability advantages.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-04-29

  This study reveals that certain p38 MAP kinase inhibitors, including RWJ 67657 (JNJ-3026582), not only block kinase activity but also promote dephosphorylation of the activation loop by stabilizing a conformation accessible to the phosphatase WIP1. These findings reshape the understanding of kinase inhibitor mechanisms and provide a blueprint for designing more selective anti-inflammatory agents.

• Assessing RG108 and Epigenetic Modulators in Pluripotency In

  2026-04-28

  This study systematically compares small-molecule epigenetic modulators—BIX-01294, Bay K8644, RG108, and valproic acid—for their ability to enhance pluripotency gene expression in vivo in the mouse brain. The findings highlight valproic acid as the most effective enhancer, while RG108’s performance contextualizes its role within in vivo reprogramming strategies.

• Protease Inhibitor Cocktail (EDTA-Free, 200X): Technical Gui

  2026-04-28

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) protects proteins from degradation during extraction and analysis, especially in workflows sensitive to divalent cations. It is best used where broad-spectrum inhibition is needed without interfering with phosphorylation or cation-dependent assays. This product is not intended for workflows requiring metalloprotease inhibition by chelation.

546 records 19/37 page Previous Next First page 上5页 1617181920 下5页 Last page